Daniel X. He, Chenpan Nie, Lei Zheng, Annie X. An, Henry Q.X. Li, Davy X. Ouyang
GITR plays a vital role in T cell proliferation and antitumor activity, and GITR agonistic antibodies are now being clinically tested in combination with immune checkpoint inhibitors.
There are, however, a lack of preclinical models available for evaluating the efficacy of therapeutic GITR agonistic antibodies, which don’t usually cross bind to mouse targets. To meet this need, we’ve developed a human GITR knock-in model, with the mouse GITR extracellular domain replaced with its human counterpart.
This poster presentation details model characterization, efficacy data for single agent and combination anti-mCTLA-4 and anti-hGITR treatment, immunoprofiling data, and rechallenge studies.
Your privacy is important to us.
We'll never share your information.